Abstract | AIMS: METHODS AND RESULTS:
STEMI patients (n=387) with > or =10 mm summed ST-deviation on electrocardiogram were randomized to receive a 48 h infusion of caldaret 57.5 mg [lower dose (LD)], caldaret 172.5 mg [higher dose (HD)], or placebo, starting before PCI. Both HD and LD were well tolerated. In 247 patients with pre-PCI TIMI 0/1, there was no effect of HD or LD on single photon emission computed tomography infarct size or ejection fraction assessed at Day 7 and Day 30. Subgroup analyses suggest that future work in patients with anterior MI might be warranted. CONCLUSION: This first human experience with caldaret prior to direct PCI for large STEMI shows a good safety profile. No evidence of efficacy was discerned. Subgroup analyses in anterior MI patients showed some effects in endpoints studied, however, these findings require confirmation in a further study if a drug effect is to be established.
|
Authors | Frits W Bär, Dan Tzivoni, Maurits T Dirksen, Antonio Fernández-Ortiz, Guy R Heyndrickx, Johannes Brachmann, Johan H C Reiber, Neelima Avasthy, Jun Tatsuno, Martin Davies, Mark G Hibberd, Mitchell W Krucoff, CASTEMI Study Group |
Journal | European heart journal
(Eur Heart J)
Vol. 27
Issue 21
Pg. 2516-23
(Nov 2006)
ISSN: 0195-668X [Print] England |
PMID | 17030521
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzenesulfonates
- Cardiotonic Agents
- Piperazines
- caldaret
|
Topics |
- Angioplasty, Balloon, Coronary
(methods)
- Benzenesulfonates
(administration & dosage)
- Cardiotonic Agents
(administration & dosage)
- Female
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Myocardial Infarction
(pathology, therapy)
- Piperazines
(administration & dosage)
- Treatment Outcome
|